Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rheosorbilact vs Ringer's Lactate in Pneumonia
NCT03824457Phase 4Completed
- Sponsor
- YURiA-PHARM
- Start
- Jan 2018
- Primary completion
- Feb 2020
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 6
01
Overview
Phase 4, randomised, single-blind trial of rheosorbilact in community acquired pneumonia (CAP) (2 arms), sponsored by YURiA-PHARM. Primary endpoint: Sequential Organ Failure Assessment Score at Day 3. Started Jan 2018; status: completed.
02
Drugs
rheosorbilact
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT03824457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824457.